133 related articles for article (PubMed ID: 21079232)
41. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
; Ginsberg JS; Davidson BL; Comp PC; Francis CW; Friedman RJ; Huo MH; Lieberman JR; Muntz JE; Raskob GE; Clements ML; Hantel S; Schnee JM; Caprini JA
J Arthroplasty; 2009 Jan; 24(1):1-9. PubMed ID: 18534438
[TBL] [Abstract][Full Text] [Related]
42. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.
Borkgren-Okonek MJ; Hart RW; Pantano JE; Rantis PC; Guske PJ; Kane JM; Gordon N; Sambol NC
Surg Obes Relat Dis; 2008; 4(5):625-31. PubMed ID: 18261965
[TBL] [Abstract][Full Text] [Related]
43. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
Amin AN; Lin J; Lenhart G; Schulman KL
Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
[TBL] [Abstract][Full Text] [Related]
44. [Venous thromboembolism prophylaxis after total hip arthroplasty].
Kučera T; Malý R; Urban K; Sponer P
Acta Chir Orthop Traumatol Cech; 2011; 78(2):101-5. PubMed ID: 21575551
[TBL] [Abstract][Full Text] [Related]
45. Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term.
de Jong PG; Coppens M; Middeldorp S
Br J Haematol; 2012 Aug; 158(4):433-41. PubMed ID: 22734929
[TBL] [Abstract][Full Text] [Related]
46. Extended thromboprophylaxis with direct oral anticoagulants for medical patients: a systematic review and meta-analysis.
Tao DL; Bien JY; DeLoughery TG; Shatzel JJ
Blood; 2017 Feb; 129(5):653-655. PubMed ID: 27998890
[No Abstract] [Full Text] [Related]
47. How long to anticoagulate?
Thachil J
QJM; 2014 Jun; 107(6):495-7. PubMed ID: 24729263
[No Abstract] [Full Text] [Related]
48. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
49. Increased enoxaparin dosing is required for obese children.
Lewis TV; Johnson PN; Nebbia AM; Dunlap M
Pediatrics; 2011 Mar; 127(3):e787-90. PubMed ID: 21321026
[TBL] [Abstract][Full Text] [Related]
50. Primary prophylaxis of venous thromboembolism in extragonadal germ-cell tumour.
Kubicek P; Boughalem E; Frere C;
J Med Vasc; 2020 Apr; 45(2):90-92. PubMed ID: 32265022
[No Abstract] [Full Text] [Related]
51. Meta-regression analysis to indirectly compare prophylaxis with dalteparin or enoxaparin in patients at high risk for venous thromboembolic events.
Dranitsaris G; Jelincic V; Choe Y
Clin Appl Thromb Hemost; 2012 Jun; 18(3):233-42. PubMed ID: 22387576
[TBL] [Abstract][Full Text] [Related]
52. Transfusions, major bleeding, and prevention of venous thromboembolism with enoxaparin or fondaparinux in thoracic surgery.
Girard P; Demaria J; Lillo-Le Louët A; Caliandro R; Le Guillou JL; Crespin M; de Sanctis A; Stern JB
Thromb Haemost; 2011 Dec; 106(6):1109-16. PubMed ID: 22012244
[TBL] [Abstract][Full Text] [Related]
53. [Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients].
Omran H; Hammerstingl C; Paar WD;
Med Klin (Munich); 2007 Oct; 102(10):809-15. PubMed ID: 17928964
[TBL] [Abstract][Full Text] [Related]
54. Increasing Enoxaparin Dosing from 30 mg to 40 mg Does Not Affect Bleeding or VTE Risk in Bariatric Surgery Patients.
Taylor R; Madion M; Kleppe K; Mancini M; Mancini G; Hutson M; Yates J; Daigle H
Am Surg; 2024 Jun; 90(6):1784-1786. PubMed ID: 38531833
[No Abstract] [Full Text] [Related]
55. Peripheral nerve block catheters and low molecular weight heparin.
Ben-David B; Chelly JE
Anesth Analg; 2007 Apr; 104(4):990-1; author reply 991-2. PubMed ID: 17377121
[No Abstract] [Full Text] [Related]
56. Dalteparin: new indication. Prophylaxis in medical patients: no advance.
Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168
[TBL] [Abstract][Full Text] [Related]
57. Aggregating and disaggregating patients in clinical trials and their subgroup analyses.
Kent DM; Lindenauer PK
Ann Intern Med; 2010 Jul; 153(1):51-2. PubMed ID: 20621903
[No Abstract] [Full Text] [Related]
58. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
Becattini C; Vedovati MC; Agnelli G
Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of extended thrombo-prophylaxis in major abdominal surgery: what does the evidence show? A meta-analysis.
Bottaro FJ; Elizondo MC; Doti C; Bruetman JE; Perez Moreno PD; Bullorsky EO; Ceresetto JM
Thromb Haemost; 2008 Jun; 99(6):1104-11. PubMed ID: 18521515
[TBL] [Abstract][Full Text] [Related]
60. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
Eriksson BI; Kakkar AK; Turpie AG; Gent M; Bandel TJ; Homering M; Misselwitz F; Lassen MR
J Bone Joint Surg Br; 2009 May; 91(5):636-44. PubMed ID: 19407299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
